At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
In Brief
A Phase 3 clinical trial evaluating JNJ-77242113, JNJ-77242113 Matching Placebo, and 2 other interventions for Plaque Psoriasis. Active but no longer recruiting, targeting 774 participants across 164 sites in 13 countries.
Signals
Detailed Summary
The purpose of the study is to see how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.
Study Details
Timeline
Arms & Interventions
Participants will receive JNJ-77242113 from Week 0 through Week 156 and deucravacitinib matching placebo from Week 0 through Week 24.
Participants will receive matching placebo for JNJ-77242113 from Week 0 through Week 16, matching placebo for deucravacitinib from Week 0 through Week 24 and JNJ-77242113 from Week 16 through Week 156.
Participants will receive deucravacitinib from Week 0 through Week 24 and matching placebo for JNJ-77242113 from Week 0 through Week 24 and JNJ-77242113 from Week 24 through Week 156.
Interventions
JNJ-77242113 will be administered orally.
JNJ-77242113 matching placebo will be administered orally.
Deucravacitinib will be administered orally.
Deucravacitinib matching placebo will be administered orally.